TrueWealth by TrueData – Live AI Summaries & Real-Time BSE/NSE Corporate Announcements
Copyright © TrueWealth 2025
Made with in INDIA
TrueData – Authorized Market Data Vendor for NSE, BSE, MCX (Official Logo)
Latest AnnouncementsToday 0
Upcoming Events
News Feed

  • No Data Found

G

Granules India Ltd

GRANULES

granulesindia.com NSE GRANULES BSE532482 ISIN: INE101D01020
₹837.55
1.15% (+9.50)
Website

granulesindia.com

NSE
NSE

GRANULES

BSE
BSE

532482

ISIN

INE101D01020

Announcement
General :: Management Change
Aug 13 2026, 02:19:56 PM

Announcement under Regulation 30 (LODR)-Change in Management

Change in Senior Management Personnel (SMP) of the Company

Granules India Ltd
Since 1984

Granules India Ltd is a leading vertically integrated pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosage forms (FDFs). The company has a diversified product portfolio with a presence across the value chain serving global pharmaceutical clients. With a core focus on high-volume, low-cost drugs, Granules India operates advanced manufacturing facilities in India and maintains significant infrastructure for quality compliance and supply chain management.

Sector
Healthcare Sector
Recent Announcements (…Last 3 Days)
G
13 Aug 2026•14:19:56
General::Management Change
Announcement under Regulation 30 (LODR)-Change in Management

Change in Senior Management Personnel (SMP) of the Company

G
06 Aug 2026•16:43:31
Outcome::AGM
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Scrutinizer''s report for the 35th AGM

G
06 Aug 2026•16:40:49
Outcome::AGM
Shareholder Meeting / Postal Ballot-Outcome of AGM

Outcome of 35th Annual General Meeting of the Company

G
04 Aug 2026•17:30:28
General::Reg 29(2) Disclosure
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India

truewealth
Request an update
Granules India Ltd
Healthcare SectorSince 1984
About

Granules India Ltd is a leading vertically integrated pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosage forms (FDFs). The company has a diversified product portfolio with a presence across the value chain serving global pharmaceutical clients. With a core focus on high-volume, low-cost drugs, Granules India operates advanced manufacturing facilities in India and maintains significant infrastructure for quality compliance and supply chain management.

Granules India’s operations span regulated markets such as North America, Europe, and emerging markets, exporting to over 60 countries. The company has established long-standing relationships with major generic and branded pharmaceutical players, leveraging strategic backward integration and process efficiencies to ensure consistent supply and cost leadership.

Business Model & Strategy

Granules India earns revenue primarily through manufacturing and exporting APIs, PFIs, and FDFs to both regulated and semi-regulated markets. Its business model is supported by an end-to-end integration—from synthesis of bulk drugs to finished dosages—ensuring scalability, quality control, and operational efficiency. The company's strategy emphasizes expansion into value-added products, increased R&D investments for complex generics, and enhancing the share of finished formulations in high-growth markets.

Growth vectors include capacity expansion in oncology and high potent APIs, broadening partnerships with global pharmaceutical companies, and leveraging its global distribution footprint.

Management Overview
13 Members
Mr.Krishna Prasad Chigurupati
Executive Director-Chairperson-MD
Mr.Kandiraju Venkata Sitaramrao
Executive Director-CEO-MD
Mrs.Uma Devi Chigurupati
Executive Director
Mr.Harsha Chigurupati
Executive Director
Mrs.Priyanka Chigurupati
Executive Director
Mr.K. B. Sankar Rao
Non-Executive - Non Independent Director
Mr.Arun Sawhney
Non-Executive - Independent Director
Mr.Saumen Chakraborty
Non-Executive - Independent Director
Mrs.Sucharita Rao Palepu
Non-Executive - Independent Director
Mr.Kapil Kumar Mehan
Non-Executive - Independent Director
Mr.Sethurathnam Ravi
Non-Executive - Independent Director
Mr.Rajiv Pritidas Kakodkar
Non-Executive - Independent Director
Ms.ChaitanyaTummala
Company Secretary & Compliance Officer
Awards & Recognition
4 Awards
  • 2024: Ranked among Forbes Asia’s 200 Best Under a Billion companies
  • 2023–2024: Recognized in the 'India’s Top 100 Best Workplaces in Pharmaceuticals, Healthcare, and Biotech' by Great Place to Work Institute
  • 2023: Received Platinum Award for Excellence in Quality at the Indian CMO Leadership Awards
  • ESG: Included in S&P Global's 2024 Sustainability Yearbook, Pharmaceutical Category
Market Information
NIFTY TOTAL MARKETNIFTY 500NIFTY SMLCAP 250NIFTY MIDSML 400NIFTY PHARMANIFTY HEALTHCARENIFTY500 MULTICAP
ISIN INE101D01020
Sector Healthcare
IndustryPharmaceuticals
Company Timeline

40+ Years of Excellence | 8 Major Milestones

1984

Founded as Granules India Limited in Hyderabad, India

1993

Commissioned first large-scale PFI manufacturing facility

1995

Initial Public Offering (IPO) listed on BSE and NSE

2004

Commenced US FDA-approved API manufacturing

2013

Acquired Auctus Pharma to expand API portfolio

2020

Launched first oncology API manufacturing facility

2023

Expanded US formulation manufacturing capacity

2024

Strengthened global presence with new R&D and innovation center

Coming Soon

The Next Evolution

Contact Information
Registered Office

15th Floor, Granules Tower, Botanical Garden Road, Kondapur

Tel: 040-69043500,

Fax: 040-23115145,

Email: investorrelations@granulesindia.com; mail@granulesindia.com

Website: granulesindia.com

Registrars

KFin Technologies Ltd

Tel: 1-800-309-4001

Email: einward.ris@kfintech.com

Corporate Actions
36
PurposeEx DateRecord DateBC StartBC End
Final Dividend
₹1.75 per share
30 Jul 2026
Thursday
30 Jul 2026
Thursday
-
-
Final Dividend
₹1.50 per share
31 Jul 2025
Thursday
31 Jul 2025
Thursday
-
-
Final Dividend
₹1.50 per share
30 Jul 2024
Tuesday
-
31 Jul 2024
Wednesday
06 Aug 2024
Tuesday
Final Dividend
₹1.50 per share
03 Aug 2023
Thursday
03 Aug 2023
Thursday
-
-
Buy Back of Shares
22 Aug 2022
Monday
23 Aug 2022
Tuesday
-
-
Final Dividend
₹0.75 per share
19 Jul 2022
Tuesday
-
21 Jul 2022
Thursday
27 Jul 2022
Wednesday
Interim Dividend
₹0.25 per share
17 Feb 2022
Thursday
18 Feb 2022
Friday
-
-
Interim Dividend
₹0.25 per share
24 Nov 2021
Wednesday
25 Nov 2021
Thursday
-
-
Interim Dividend
₹0.25 per share
05 Aug 2021
Thursday
06 Aug 2021
Friday
-
-
Final Dividend
₹0.75 per share
28 Jul 2021
Wednesday
-
30 Jul 2021
Friday
05 Aug 2021
Thursday
Interim Dividend
₹0.25 per share
08 Feb 2021
Monday
09 Feb 2021
Tuesday
-
-
Interim Dividend
₹0.25 per share
28 Oct 2020
Wednesday
30 Oct 2020
Friday
-
-
Final Dividend
₹0.25 per share
05 Aug 2020
Wednesday
-
07 Aug 2020
Friday
13 Aug 2020
Thursday
Interim Dividend
₹0.25 per share
28 Jul 2020
Tuesday
29 Jul 2020
Wednesday
-
-
Buy Back of Shares
19 Mar 2020
Thursday
20 Mar 2020
Friday
-
-
Interim Dividend
₹0.25 per share
30 Jan 2020
Thursday
31 Jan 2020
Friday
-
-
Interim Dividend
₹0.25 per share
31 Oct 2019
Thursday
02 Nov 2019
Saturday
-
-
Final Dividend
₹0.25 per share
21 Aug 2019
Wednesday
-
23 Aug 2019
Friday
29 Aug 2019
Thursday
Interim Dividend
₹0.25 per share
08 Aug 2019
Thursday
09 Aug 2019
Friday
-
-
Interim Dividend
₹0.25 per share
07 Feb 2019
Thursday
08 Feb 2019
Friday
-
-
Interim Dividend
₹0.25 per share
06 Nov 2018
Tuesday
10 Nov 2018
Saturday
-
-
Final Dividend
₹0.25 per share
29 Aug 2018
Wednesday
-
31 Aug 2018
Friday
06 Sep 2018
Thursday
Interim Dividend
₹0.25 per share
01 Aug 2018
Wednesday
02 Aug 2018
Thursday
-
-
Interim Dividend
₹0.25 per share
20 Feb 2018
Tuesday
21 Feb 2018
Wednesday
-
-
Interim Dividend
₹0.25 per share
20 Nov 2017
Monday
21 Nov 2017
Tuesday
-
-
Final Dividend
₹0.25 per share
20 Sep 2017
Wednesday
-
22 Sep 2017
Friday
28 Sep 2017
Thursday
Interim Dividend
₹0.25 per share
23 Aug 2017
Wednesday
25 Aug 2017
Friday
-
-
Interim Dividend
₹0.25 per share
07 Feb 2017
Tuesday
08 Feb 2017
Wednesday
-
-
Interim Dividend
₹0.20 per share
03 Nov 2016
Thursday
05 Nov 2016
Saturday
-
-
Interim Dividend
₹0.20 per share
23 Aug 2016
Tuesday
24 Aug 2016
Wednesday
-
-
Final Dividend
₹0.20 per share
03 Aug 2016
Wednesday
-
05 Aug 2016
Friday
11 Aug 2016
Thursday
Interim Dividend
₹0.15 per share
08 Feb 2016
Monday
09 Feb 2016
Tuesday
-
-
Interim Dividend
₹0.15 per share
09 Nov 2015
Monday
11 Nov 2015
Wednesday
-
-
Final Dividend
₹0.50 per share
05 Aug 2015
Wednesday
-
07 Aug 2015
Friday
13 Aug 2015
Thursday
Interim Dividend
₹0.15 per share
05 Aug 2015
Wednesday
-
07 Aug 2015
Friday
13 Aug 2015
Thursday
Stock Split From Rs.10/- to Rs.1/-
23 Mar 2015
Monday
24 Mar 2015
Tuesday
-
-
Interim Dividend
Final Dividend
Dividend
Bonus
Split
Rights Issue
Other
.dsf..
Market Cap
₹20,765 Cr.
Curr. Price
₹838
52W High/Low
₹910 / 468
P/E (TTM)
30.97
Book Value
₹205.21
Price To Book Ratio
4.08
ROE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
11.7 %
ROCE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
54.39 %
EPS (TTM)
blog-img
What is EPS & what is its significance?
₹27.06
Face Value
₹1.00
Dividend Yield
0.21 %
Manage Ratio
11 ratios selected

Date Basis

Time Range

EPS
truewealth
Request an update
FINANCIALS
Revenue
+19.7%
5,365.6 Cr
3Y +19%
5Y +66%
HIST AVG
Operating Income
+25.4%
1,185.1 Cr
3Y +30%
5Y +39%
HIST AVG
Net Income
+18.6%
595.0 Cr
3Y +15%
5Y +8%
HIST AVG
EPS
+18.3%
24.0
3Y +16%
5Y +11%
HIST AVG
Op. Cash Flow
-8.5%
793.0 Cr
3Y +7%
5Y +83%
HIST AVG
GRANULES - Annual Results

Consolidated Figures in Rs. Crores

Annual Results+Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Income + - - - 2,306 2,635 3,264 3,783 4,526 4,511 4,495 5,3865,639
Expenses + - - - 2,029 2,237 2,560 3,225 3,839 3,964 3,865 4,5914,774
Profit + - - - 236 335 549 413 517 405 502 595662
Tax +---89116155145171142159190219
EPS + - - - 9 13 22 17 21 17 21 247.26
Ratios +-
Cash Flow

Consolidated Figures in Rs. Crores

Annual Cash FlowMar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

-
Cash Flow Operating-----432332739439867793-
Cash Flow Investing------277-380-191-360-691-773-
Cash Flow Financing------299190-4408-93379-
Cash Increase Decrease------1441431079085412-
Net Cash And Cash Equivalent-----18642185292381469-
Balance Sheet

Consolidated Figures in Rs. Crores

Annual Balance Sheet+Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-
Assets + - - - 2,983 3,301 3,713 4,513 4,905 5,521 6,253 7,720-
Equity And Liabilities + - - - 2,983 3,301 3,713 4,513 4,905 5,521 6,253 7,720-
Shareholding Pattern

Numbers in Percentages

Quarterly SHP

Announcement Date

Mar 2016

12 Apr '16

Mar 2017

31 Mar '17

Mar 2018

31 Mar '18

Mar 2019

05 Apr '19

Mar 2020

10 Apr '20

Mar 2021

07 Apr '21

Mar 2022

05 Apr '22

Mar 2023

07 Apr '23

Mar 2024

15 Apr '24

Mar 2025

07 Apr '25

Mar 2026

06 Apr '26

-
Goverments ------------
Promoter And Promoter Group - - - 42.90% 42.86% 42.04% 41.98% 42.02% 41.96% 38.84% 38.02%-
Non Institutions ---41.32%32.43%33.36%30.85%29.05%27.76%23.57%29.66%-
FII - - - - - - - 23.90% 19.57% 15.15% 15.31%-
DII - - - - - - - 5.03% 10.70% 22.45% 17.01%-
Total ---100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-

Granules India Ltd

Pharmaceuticals
Last Updated: June 18, 2025

Granules India Ltd

Granules India Ltd is a leading vertically integrated pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosage forms (FDFs). The company has a diversified product portfolio with a presence across the value chain serving global pharmaceutical clients. With a core focus on high-volume, low-cost drugs, Granules India operates advanced manufacturing facilities in India and maintains significant infrastructure for quality compliance and supply chain management.

Granules India’s operations span regulated markets such as North America, Europe, and emerging markets, exporting to over 60 countries. The company has established long-standing relationships with major generic and branded pharmaceutical players, leveraging strategic backward integration and process efficiencies to ensure consistent supply and cost leadership.

Healthcare SectorSince 1984
Business Model & Strategy

Granules India earns revenue primarily through manufacturing and exporting APIs, PFIs, and FDFs to both regulated and semi-regulated markets. Its business model is supported by an end-to-end integration—from synthesis of bulk drugs to finished dosages—ensuring scalability, quality control, and operational efficiency. The company's strategy emphasizes expansion into value-added products, increased R&D investments for complex generics, and enhancing the share of finished formulations in high-growth markets.

Growth vectors include capacity expansion in oncology and high potent APIs, broadening partnerships with global pharmaceutical companies, and leveraging its global distribution footprint.

Management Overview 13 Total Members
logo
Mr.Krishna Prasad Chigurupati
Executive Director-Chairperson-MD
logo
Mr.Kandiraju Venkata Sitaramrao
Executive Director-CEO-MD
logo
Mrs.Uma Devi Chigurupati
Executive Director
logo
Mr.Harsha Chigurupati
Executive Director
logo
Mrs.Priyanka Chigurupati
Executive Director
logo
Mr.K. B. Sankar Rao
Non-Executive - Non Independent Director
logo
Mr.Arun Sawhney
Non-Executive - Independent Director
logo
Mr.Saumen Chakraborty
Non-Executive - Independent Director
logo
Mrs.Sucharita Rao Palepu
Non-Executive - Independent Director
logo
Mr.Kapil Kumar Mehan
Non-Executive - Independent Director
logo
Mr.Sethurathnam Ravi
Non-Executive - Independent Director
logo
Mr.Rajiv Pritidas Kakodkar
Non-Executive - Independent Director
logo
Ms.ChaitanyaTummala
Company Secretary & Compliance Officer
Awards & Recognition 4 Awards
2024: Ranked among Forbes Asia’s 200 Best Under a Billion companies
2023–2024: Recognized in the 'India’s Top 100 Best Workplaces in Pharmaceuticals, Healthcare, and Biotech' by Great Place to Work Institute
2023: Received Platinum Award for Excellence in Quality at the Indian CMO Leadership Awards
ESG: Included in S&P Global's 2024 Sustainability Yearbook, Pharmaceutical Category
Market Information
Included In
NIFTY TOTAL MARKETNIFTY 500NIFTY SMLCAP 250NIFTY MIDSML 400NIFTY PHARMANIFTY HEALTHCARENIFTY500 MULTICAP
Details
ISIN: INE101D01020
Sector: Healthcare
Industry: Pharmaceuticals
Company Timeline
40+ Years of Excellence
8 Major Milestones
1984
Founded as Granules India Limited in Hyderabad, India
1993
Commissioned first large-scale PFI manufacturing facility
1995
Initial Public Offering (IPO) listed on BSE and NSE
2004
Commenced US FDA-approved API manufacturing
2013
Acquired Auctus Pharma to expand API portfolio
2020
Launched first oncology API manufacturing facility
2023
Expanded US formulation manufacturing capacity
2024
Strengthened global presence with new R&D and innovation center
Coming Soon: The Next Evolution
Contact Information
Registered Office
15th Floor, Granules Tower, Botanical Garden Road, Kondapur
Tel: 040-69043500,
Fax: 040-23115145,
Email: investorrelations@granulesindia.com; mail@granulesindia.com
Website: granulesindia.com
Registrars
KFin Technologies Ltd
Tel: 1-800-309-4001
Email: einward.ris@kfintech.com

Peer Comparison

Part ofNIFTY TOTAL MARKETNIFTY 500NIFTY SMLCAP 250NIFTY MIDSML 400NIFTY PHARMANIFTY HEALTHCARENIFTY500 MULTICAP
S.No.Company NameCMP (₹)Market Cap (₹ Cr)Div Yld (%)NP Qtr (₹ Cr)Qtr Profit Var (%)Sales Qtr (₹ Cr)Qtr Sales Var (%)ROCE (%)ROE (%)Book Value (₹)EPS TTM (₹)TTMPE Ratio (₹)
Not Found Data

Coming Soon

Heatmap View

Premium Feature
CompanyCMP (₹)MCap (₹ Cr)EPS TTM (₹)
Not Found Data

Financial Ratios

Premium Feature
Company NameP/E (TTM)EPS (₹)D/ENPMGPMROE (%)ROCE (%)P/B
Not Found Data

Coming Soon